GlassScriptPhysician profile
Steven A Naprawa
NPI 1669436341
$560,606.87
in general payments reported to CMS, 2019-2025
20 companies · $153K in 2025
The $153K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74K · 2020: $35K · 2021: $44K · 2022: $63K · 2023: $110K · 2024: $82K · 2025: $153K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $289K · Travel and Lodging: $25K · Consulting Fee: $20K · Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $289,241.50 |
| Travel and Lodging | $25,200.20 |
| Consulting Fee | $19,713.00 |
| Food and Beverage | $10,486.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $532,694.71 | 2019-2025 | Ingrezza |
| Abbvie INC. | $23,618.57 | 2021-2025 | |
| Alkermes, INC. | $787.02 | 2019-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $616.52 | 2019-2023 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $614.18 | 2019-2025 | Invega Trinza, Invega Sustenna, Invega |
| Otsuka America Pharmaceutical, INC. | $416.66 | 2019-2023 | Abilify Maintena, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $335.20 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $319.77 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $250.89 | 2019-2023 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $194.26 | 2020-2025 | Caplyta |
| Axsome Therapeutics, INC. | $166.89 | 2023-2025 | Auvelity |
| Lundbeck LLC | $152.10 | 2020-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $121.96 | 2020-2023 | Trintellix |
| Indivior INC. | $88.88 | 2019-2022 | |
| Allergan, INC. | $81.27 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $53.55 | 2022-2023 | Qelbree |
| Corium, LLC | $43.25 | 2022-2023 | Azstarys |
| Avanir Pharmaceuticals, INC. | $22.71 | 2022 | |
| Adlon Therapeutics L.P. | $15.29 | 2020 | |
| Almatica Pharma LLC | $13.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Naprawa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.